top of page

Checking in with Imvax ahead of key P2b data in glioblastoma next year of its personalized treatment that is delivered via implantable biodiffusion chambers

CEO John Furey describes how the therapy works, like a combination of "immunotherapy and cell therapy." He reviews phase 1 data, and previews key P2b data that is currently scheduled for mid-2025.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

KH_Logo_Horizontal_Tagline_Black-1.png

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

bottom of page